サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1117390

世界のアダリムマブ市場：考察と予測 (2028年まで)

Global Adalimumab Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 123 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
世界のアダリムマブ市場：考察と予測 (2028年まで)
出版日: 2022年08月22日
発行: QYResearch
ページ情報: 英文 123 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、アダリムマブ (Adalimumab) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • アダリムマブの製品概要
  • 市場：タイプ別
    • 世界のアダリムマブの市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Adalimumab
    • Adalimumab Biosimilar
  • 市場：アプリケーション別
    • 世界のアダリムマブの市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Adults
    • Children
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界のアダリムマブの販売 推定および予測 2017-2028
  • 世界のアダリムマブの収益 推定および予測 2017-2028
  • 世界のアダリムマブの収益：地域別: 2017 VS 2021 VS 2028
  • 世界のアダリムマブの販売：地域別
    • 世界のアダリムマブの販売：地域別 (2017-2022)
    • 世界の販売 アダリムマブ ：地域別 (2023-2028)
  • 世界のアダリムマブの収益：地域別
    • 世界のアダリムマブの収益：地域別 (2017-2022)
    • 世界のアダリムマブの収益：地域別 (2023-2028)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第3章 競合：メーカー別

  • 世界のアダリムマブの販売：メーカー別
    • 世界のアダリムマブの上位メーカー：販売別 (2017-2022)
    • 世界のアダリムマブの販売市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5メーカー： アダリムマブ2021
  • 世界のアダリムマブの収益：メーカー別
    • 世界のアダリムマブの収益：メーカー別 (2017-2022)
    • 世界のアダリムマブの収益市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5企業： アダリムマブの収益 2021
  • 世界のアダリムマブの販売価格：メーカー別 (2017-2022)
  • 競合情勢の分析
    • メーカーの市場集中度 (CR5 and HHI)
    • 世界のアダリムマブの市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
    • 世界のアダリムマブのメーカーの地理的分布
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界のアダリムマブの販売：タイプ別
    • 世界のアダリムマブの販売実績：タイプ別 (2017-2022)
    • 世界のアダリムマブの販売予測：タイプ別 (2023-2028)
    • 世界のアダリムマブの販売市場シェア：タイプ別 (2017-2028)
  • 世界のアダリムマブの収益：タイプ別
    • 世界のアダリムマブの収益実績：タイプ別 (2017-2022)
    • 世界のアダリムマブの収益予測：タイプ別 (2023-2028)
    • 世界のアダリムマブの収益市場シェア：タイプ別 (2017-2028)
  • 世界のアダリムマブの価格：タイプ別
    • 世界のアダリムマブの価格：タイプ別 (2017-2022)
    • 世界のアダリムマブの価格予測：タイプ別 (2023-2028)

第5章 市場規模：アプリケーション別

  • 世界のアダリムマブの販売：アプリケーション別
    • 世界のアダリムマブの販売実績：アプリケーション別 (2017-2022)
    • 世界のアダリムマブの販売予測：アプリケーション別 (2023-2028)
    • 世界のアダリムマブの販売市場シェア：アプリケーション別 (2017-2028)
  • 世界のアダリムマブの収益：アプリケーション別
    • 世界のアダリムマブの収益実績：アプリケーション別 (2017-2022)
    • 世界のアダリムマブの収益予測：アプリケーション別 (2023-2028)
    • 世界のアダリムマブの収益市場シェア：アプリケーション別 (2017-2028)
  • 世界のアダリムマブの価格：アプリケーション別
    • 世界のアダリムマブの価格：アプリケーション別 (2017-2022)
    • 世界のアダリムマブの価格予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米のアダリムマブ 市場規模：タイプ別
    • 北米のアダリムマブの販売：タイプ別 (2017-2028)
    • 北米のアダリムマブの収益：タイプ別 (2017-2028)
  • 北米のアダリムマブ 市場規模：アプリケーション別
    • 北米のアダリムマブの販売：アプリケーション別 (2017-2028)
    • 北米のアダリムマブの収益：アプリケーション別 (2017-2028)
  • 北米のアダリムマブ 市場規模：国別
    • 北米のアダリムマブの販売：国別 (2017-2028)
    • 北米のアダリムマブの収益：国別 (2017-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州のアダリムマブ 市場規模：タイプ別
    • 欧州のアダリムマブの販売：タイプ別 (2017-2028)
    • 欧州のアダリムマブの収益：タイプ別 (2017-2028)
  • 欧州のアダリムマブ 市場規模：アプリケーション別
    • 欧州のアダリムマブの販売：アプリケーション別 (2017-2028)
    • 欧州のアダリムマブの収益：アプリケーション別 (2017-2028)
  • 欧州のアダリムマブ 市場規模：国別
    • 欧州のアダリムマブの販売：国別 (2017-2028)
    • 欧州のアダリムマブの収益：国別 (2017-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋

  • アジア太平洋のアダリムマブ 市場規模：タイプ別
    • アジア太平洋のアダリムマブの販売：タイプ別 (2017-2028)
    • アジア太平洋のアダリムマブの収益：タイプ別 (2017-2028)
  • アジア太平洋のアダリムマブ 市場規模：アプリケーション別
    • アジア太平洋のアダリムマブの販売：アプリケーション別 (2017-2028)
    • アジア太平洋のアダリムマブの収益：アプリケーション別 (2017-2028)
  • アジア太平洋のアダリムマブ 市場規模：地域別
    • アジア太平洋のアダリムマブの販売：地域別 (2017-2028)
    • アジア太平洋のアダリムマブの収益：地域別 (2017-2028)
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • 台湾
    • インドネシア
    • タイ
    • マレーシア
    • フィリピン

第9章 ラテンアメリカ

  • ラテンアメリカのアダリムマブ 市場規模：タイプ別
    • ラテンアメリカのアダリムマブの販売：タイプ別 (2017-2028)
    • ラテンアメリカのアダリムマブの収益：タイプ別 (2017-2028)
  • ラテンアメリカのアダリムマブ 市場規模：アプリケーション別
    • ラテンアメリカのアダリムマブの販売：アプリケーション別 (2017-2028)
    • ラテンアメリカのアダリムマブの収益：アプリケーション別 (2017-2028)
  • ラテンアメリカのアダリムマブ 市場規模：国別
    • ラテンアメリカのアダリムマブの販売：国別 (2017-2028)
    • ラテンアメリカのアダリムマブの収益：国別 (2017-2028)
    • メキシコ
    • ブラジル
    • アルゼンチン

第10章 中東・アフリカ

  • 中東・アフリカのアダリムマブ 市場規模：タイプ別
    • 中東・アフリカのアダリムマブの販売：タイプ別 (2017-2028)
    • 中東・アフリカのアダリムマブの収益：タイプ別 (2017-2028)
  • 中東・アフリカのアダリムマブ 市場規模：アプリケーション別
    • 中東・アフリカのアダリムマブの販売：アプリケーション別 (2017-2028)
    • 中東・アフリカのアダリムマブの収益：アプリケーション別 (2017-2028)
  • 中東・アフリカのアダリムマブ 市場規模：国別
    • 中東・アフリカのアダリムマブの販売：国別 (2017-2028)
    • 中東・アフリカのアダリムマブの収益：国別 (2017-2028)
    • トルコ
    • サウジアラビア

第11章 企業プロファイル

  • AbbVie
  • Amgen
  • Sandoz
  • Boehringer Ingelheim
  • Mylan
  • Biogen

第12章 業界チェーンと販売チャネルの分析

  • アダリムマブ 業界チェーン分析
  • アダリムマブ 主要原材料分析
    • 主要原材料分析
    • 原材料の主要サプライヤー
  • アダリムマブ 生産形態とプロセス
  • アダリムマブ 販売およびマーケティング
    • アダリムマブ 販売チャネル
    • アダリムマブ 卸業者
  • アダリムマブ 顧客

第13章 市場の促進要因, 機会, 課題とリスク要因の分析

  • アダリムマブ 業界動向
  • アダリムマブ 市場の促進要因
  • アダリムマブ 市場の課題
  • アダリムマブ 市場の抑制要因

第14章 世界のアダリムマブの主な市場調査結果

第15章 付録

図表
  • Table 1. Global Adalimumab Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 2. Major Manufacturers of Adalimumab
  • Table 3. Major Manufacturers of Adalimumab Biosimilar
  • Table 4. Global Adalimumab Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 5. Global Adalimumab Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
  • Table 6. Global Adalimumab Sales by Region (2017-2022) & (K Units)
  • Table 7. Global Adalimumab Sales Market Share by Region (2017-2022)
  • Table 8. Global Adalimumab Sales by Region (2023-2028) & (K Units)
  • Table 9. Global Adalimumab Sales Market Share by Region (2023-2028)
  • Table 10. Global Adalimumab Revenue by Region (2017-2022) & (US$ Million)
  • Table 11. Global Adalimumab Revenue Market Share by Region (2017-2022)
  • Table 12. Global Adalimumab Revenue by Region (2023-2028) & (US$ Million)
  • Table 13. Global Adalimumab Revenue Market Share by Region (2023-2028)
  • Table 14. Global Adalimumab Sales by Manufacturers (2017-2022) & (K Units)
  • Table 15. Global Adalimumab Sales Share by Manufacturers (2017-2022)
  • Table 16. Global Adalimumab Revenue by Manufacturers (2017-2022) & (US$ Million)
  • Table 17. Global Adalimumab Revenue Share by Manufacturers (2017-2022)
  • Table 18. Adalimumab Price by Manufacturers (2017-2022) &(USD/Unit)
  • Table 19. Global Adalimumab Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 20. Global Adalimumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab as of 2021)
  • Table 21. Adalimumab Manufacturing Base Distribution and Headquarters
  • Table 22. Manufacturers Adalimumab Product Offered
  • Table 23. Date of Manufacturers Enter into Adalimumab Market
  • Table 24. Mergers & Acquisitions, Expansion Plans
  • Table 25. Global Adalimumab Sales by Type (2017-2022) & (K Units)
  • Table 26. Global Adalimumab Sales by Type (2023-2028) & (K Units)
  • Table 27. Global Adalimumab Sales Share by Type (2017-2022)
  • Table 28. Global Adalimumab Sales Share by Type (2023-2028)
  • Table 29. Global Adalimumab Revenue by Type (2017-2022) & (US$ Million)
  • Table 30. Global Adalimumab Revenue by Type (2023-2028) & (US$ Million)
  • Table 31. Global Adalimumab Revenue Share by Type (2017-2022)
  • Table 32. Global Adalimumab Revenue Share by Type (2023-2028)
  • Table 33. Adalimumab Price by Type (2017-2022) & (USD/Unit)
  • Table 34. Global Adalimumab Price Forecast by Type (2023-2028) & (USD/Unit)
  • Table 35. Global Adalimumab Sales by Application (2017-2022) & (K Units)
  • Table 36. Global Adalimumab Sales by Application (2023-2028) & (K Units)
  • Table 37. Global Adalimumab Sales Share by Application (2017-2022)
  • Table 38. Global Adalimumab Sales Share by Application (2023-2028)
  • Table 39. Global Adalimumab Revenue by Application (2017-2022) & (US$ Million)
  • Table 40. Global Adalimumab Revenue by Application (2023-2028) & (US$ Million)
  • Table 41. Global Adalimumab Revenue Share by Application (2017-2022)
  • Table 42. Global Adalimumab Revenue Share by Application (2023-2028)
  • Table 43. Adalimumab Price by Application (2017-2022) & (USD/Unit)
  • Table 44. Global Adalimumab Price Forecast by Application (2023-2028) & (USD/Unit)
  • Table 45. North America Adalimumab Sales by Type (2017-2022) & (K Units)
  • Table 46. North America Adalimumab Sales by Type (2023-2028) & (K Units)
  • Table 47. North America Adalimumab Revenue by Type (2017-2022) & (US$ Million)
  • Table 48. North America Adalimumab Revenue by Type (2023-2028) & (US$ Million)
  • Table 49. North America Adalimumab Sales by Application (2017-2022) & (K Units)
  • Table 50. North America Adalimumab Sales by Application (2023-2028) & (K Units)
  • Table 51. North America Adalimumab Revenue by Application (2017-2022) & (US$ Million)
  • Table 52. North America Adalimumab Revenue by Application (2023-2028) & (US$ Million)
  • Table 53. North America Adalimumab Sales by Country (2017-2022) & (K Units)
  • Table 54. North America Adalimumab Sales by Country (2023-2028) & (K Units)
  • Table 55. North America Adalimumab Revenue by Country (2017-2022) & (US$ Million)
  • Table 56. North America Adalimumab Revenue by Country (2023-2028) & (US$ Million)
  • Table 57. Europe Adalimumab Sales by Type (2017-2022) & (K Units)
  • Table 58. Europe Adalimumab Sales by Type (2023-2028) & (K Units)
  • Table 59. Europe Adalimumab Revenue by Type (2017-2022) & (US$ Million)
  • Table 60. Europe Adalimumab Revenue by Type (2023-2028) & (US$ Million)
  • Table 61. Europe Adalimumab Sales by Application (2017-2022) & (K Units)
  • Table 62. Europe Adalimumab Sales by Application (2023-2028) & (K Units)
  • Table 63. Europe Adalimumab Revenue by Application (2017-2022) & (US$ Million)
  • Table 64. Europe Adalimumab Revenue by Application (2023-2028) & (US$ Million)
  • Table 65. Europe Adalimumab Sales by Country (2017-2022) & (K Units)
  • Table 66. Europe Adalimumab Sales by Country (2023-2028) & (K Units)
  • Table 67. Europe Adalimumab Revenue by Country (2017-2022) & (US$ Million)
  • Table 68. Europe Adalimumab Revenue by Country (2023-2028) & (US$ Million)
  • Table 69. Asia Pacific Adalimumab Sales by Type (2017-2022) & (K Units)
  • Table 70. Asia Pacific Adalimumab Sales by Type (2023-2028) & (K Units)
  • Table 71. Asia Pacific Adalimumab Revenue by Type (2017-2022) & (US$ Million)
  • Table 72. Asia Pacific Adalimumab Revenue by Type (2023-2028) & (US$ Million)
  • Table 73. Asia Pacific Adalimumab Sales by Application (2017-2022) & (K Units)
  • Table 74. Asia Pacific Adalimumab Sales by Application (2023-2028) & (K Units)
  • Table 75. Asia Pacific Adalimumab Revenue by Application (2017-2022) & (US$ Million)
  • Table 76. Asia Pacific Adalimumab Revenue by Application (2023-2028) & (US$ Million)
  • Table 77. Asia Pacific Adalimumab Sales by Region (2017-2022) & (K Units)
  • Table 78. Asia Pacific Adalimumab Sales by Region (2023-2028) & (K Units)
  • Table 79. Asia Pacific Adalimumab Revenue by Region (2017-2022) & (US$ Million)
  • Table 80. Asia Pacific Adalimumab Revenue by Region (2023-2028) & (US$ Million)
  • Table 81. Latin America Adalimumab Sales by Type (2017-2022) & (K Units)
  • Table 82. Latin America Adalimumab Sales by Type (2023-2028) & (K Units)
  • Table 83. Latin America Adalimumab Revenue by Type (2017-2022) & (US$ Million)
  • Table 84. Latin America Adalimumab Revenue by Type (2023-2028) & (US$ Million)
  • Table 85. Latin America Adalimumab Sales by Application (2017-2022) & (K Units)
  • Table 86. Latin America Adalimumab Sales by Application (2023-2028) & (K Units)
  • Table 87. Latin America Adalimumab Revenue by Application (2017-2022) & (US$ Million)
  • Table 88. Latin America Adalimumab Revenue by Application (2023-2028) & (US$ Million)
  • Table 89. Latin America Adalimumab Sales by Country (2017-2022) & (K Units)
  • Table 90. Latin America Adalimumab Sales by Country (2023-2028) & (K Units)
  • Table 91. Latin America Adalimumab Revenue by Country (2017-2022) & (US$ Million)
  • Table 92. Latin America Adalimumab Revenue by Country (2023-2028) & (US$ Million)
  • Table 93. Middle East and Africa Adalimumab Sales by Type (2017-2022) & (K Units)
  • Table 94. Middle East and Africa Adalimumab Sales by Type (2023-2028) & (K Units)
  • Table 95. Middle East and Africa Adalimumab Revenue by Type (2017-2022) & (US$ Million)
  • Table 96. Middle East and Africa Adalimumab Revenue by Type (2023-2028) & (US$ Million)
  • Table 97. Middle East and Africa Adalimumab Sales by Application (2017-2022) & (K Units)
  • Table 98. Middle East and Africa Adalimumab Sales by Application (2023-2028) & (K Units)
  • Table 99. Middle East and Africa Adalimumab Revenue by Application (2017-2022) & (US$ Million)
  • Table 100. Middle East and Africa Adalimumab Revenue by Application (2023-2028) & (US$ Million)
  • Table 101. Middle East and Africa Adalimumab Sales by Country (2017-2022) & (K Units)
  • Table 102. Middle East and Africa Adalimumab Sales by Country (2023-2028) & (K Units)
  • Table 103. Middle East and Africa Adalimumab Revenue by Country (2017-2022) & (US$ Million)
  • Table 104. Middle East and Africa Adalimumab Revenue by Country (2023-2028) & (US$ Million)
  • Table 105. AbbVie Corporation Information
  • Table 106. AbbVie Description and Major Businesses
  • Table 107. AbbVie Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 108. AbbVie Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 109. AbbVie Recent Developments
  • Table 110. Amgen Corporation Information
  • Table 111. Amgen Description and Major Businesses
  • Table 112. Amgen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 113. Amgen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 114. Amgen Recent Developments
  • Table 115. Sandoz Corporation Information
  • Table 116. Sandoz Description and Major Businesses
  • Table 117. Sandoz Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 118. Sandoz Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 119. Sandoz Recent Developments
  • Table 120. Boehringer Ingelheim Corporation Information
  • Table 121. Boehringer Ingelheim Description and Major Businesses
  • Table 122. Boehringer Ingelheim Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 123. Boehringer Ingelheim Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 124. Boehringer Ingelheim Recent Developments
  • Table 125. Mylan Corporation Information
  • Table 126. Mylan Description and Major Businesses
  • Table 127. Mylan Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 128. Mylan Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 129. Mylan Recent Developments
  • Table 130. Biogen Corporation Information
  • Table 131. Biogen Description and Major Businesses
  • Table 132. Biogen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
  • Table 133. Biogen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 134. Biogen Recent Developments
  • Table 135. Key Raw Materials Lists
  • Table 136. Raw Materials Key Suppliers Lists
  • Table 137. Adalimumab Distributors List
  • Table 138. Adalimumab Customers List
  • Table 139. Adalimumab Market Trends
  • Table 140. Adalimumab Market Drivers
  • Table 141. Adalimumab Market Challenges
  • Table 142. Adalimumab Market Restraints
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Adalimumab Product Picture
  • Figure 3. Global Adalimumab Market Share by Type in 2021 & 2028
  • Figure 3. Adalimumab Product Picture
  • Figure 4. Adalimumab Biosimilar Product Picture
  • Figure 5. Global Adalimumab Market Share by Application in 2021 & 2028
  • Figure 6. Adults
  • Figure 7. Children
  • Figure 8. Adalimumab Report Years Considered
  • Figure 9. Global Adalimumab Sales 2017-2028 (K Units)
  • Figure 10. Global Adalimumab Revenue, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 11. Global Adalimumab Revenue 2017-2028 (US$ Million)
  • Figure 12. Global Adalimumab Revenue Market Share by Region in Percentage: 2021 Versus 2028
  • Figure 13. Global Adalimumab Sales Market Share by Region (2017-2022)
  • Figure 14. Global Adalimumab Sales Market Share by Region (2023-2028)
  • Figure 15. North America Adalimumab Sales YoY (2017-2028) & (K Units)
  • Figure 16. North America Adalimumab Revenue YoY (2017-2028) & (US$ Million)
  • Figure 17. Europe Adalimumab Sales YoY (2017-2028) & (K Units)
  • Figure 18. Europe Adalimumab Revenue YoY (2017-2028) & (US$ Million)
  • Figure 19. Asia-Pacific Adalimumab Sales YoY (2017-2028) & (K Units)
  • Figure 20. Asia-Pacific Adalimumab Revenue YoY (2017-2028) & (US$ Million)
  • Figure 21. Latin America Adalimumab Sales YoY (2017-2028) & (K Units)
  • Figure 22. Latin America Adalimumab Revenue YoY (2017-2028) & (US$ Million)
  • Figure 23. Middle East & Africa Adalimumab Sales YoY (2017-2028) & (K Units)
  • Figure 24. Middle East & Africa Adalimumab Revenue YoY (2017-2028) & (US$ Million)
  • Figure 25. The Adalimumab Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
  • Figure 26. The Top 5 and 10 Largest Manufacturers of Adalimumab in the World: Market Share by Adalimumab Revenue in 2021
  • Figure 27. Global Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
  • Figure 28. Global Adalimumab Sales Market Share by Type (2017-2028)
  • Figure 29. Global Adalimumab Revenue Market Share by Type (2017-2028)
  • Figure 30. Global Adalimumab Sales Market Share by Application (2017-2028)
  • Figure 31. Global Adalimumab Revenue Market Share by Application (2017-2028)
  • Figure 32. North America Adalimumab Sales Market Share by Type (2017-2028)
  • Figure 33. North America Adalimumab Revenue Market Share by Type (2017-2028)
  • Figure 34. North America Adalimumab Sales Market Share by Application (2017-2028)
  • Figure 35. North America Adalimumab Revenue Market Share by Application (2017-2028)
  • Figure 36. North America Adalimumab Sales Share by Country (2017-2028)
  • Figure 37. North America Adalimumab Revenue Share by Country (2017-2028)
  • Figure 38. U.S. Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 39. Canada Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 40. Europe Adalimumab Sales Market Share by Type (2017-2028)
  • Figure 41. Europe Adalimumab Revenue Market Share by Type (2017-2028)
  • Figure 42. Europe Adalimumab Sales Market Share by Application (2017-2028)
  • Figure 43. Europe Adalimumab Revenue Market Share by Application (2017-2028)
  • Figure 44. Europe Adalimumab Sales Share by Country (2017-2028)
  • Figure 45. Europe Adalimumab Revenue Share by Country (2017-2028)
  • Figure 46. Germany Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 47. France Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 48. U.K. Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 49. Italy Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 50. Russia Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 51. Asia Pacific Adalimumab Sales Market Share by Type (2017-2028)
  • Figure 52. Asia Pacific Adalimumab Revenue Market Share by Type (2017-2028)
  • Figure 53. Asia Pacific Adalimumab Sales Market Share by Application (2017-2028)
  • Figure 54. Asia Pacific Adalimumab Revenue Market Share by Application (2017-2028)
  • Figure 55. Asia Pacific Adalimumab Sales Share by Region (2017-2028)
  • Figure 56. Asia Pacific Adalimumab Revenue Share by Region (2017-2028)
  • Figure 57. China Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 58. Japan Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 59. South Korea Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 60. India Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 61. Australia Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 62. Taiwan Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 63. Indonesia Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 64. Thailand Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 65. Malaysia Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 66. Philippines Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 67. Latin America Adalimumab Sales Market Share by Type (2017-2028)
  • Figure 68. Latin America Adalimumab Revenue Market Share by Type (2017-2028)
  • Figure 69. Latin America Adalimumab Sales Market Share by Application (2017-2028)
  • Figure 70. Latin America Adalimumab Revenue Market Share by Application (2017-2028)
  • Figure 71. Latin America Adalimumab Sales Share by Country (2017-2028)
  • Figure 72. Latin America Adalimumab Revenue Share by Country (2017-2028)
  • Figure 73. Mexico Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 74. Brazil Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 75. Argentina Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 76. Middle East and Africa Adalimumab Sales Market Share by Type (2017-2028)
  • Figure 77. Middle East and Africa Adalimumab Revenue Market Share by Type (2017-2028)
  • Figure 78. Middle East and Africa Adalimumab Sales Market Share by Application (2017-2028)
  • Figure 79. Middle East and Africa Adalimumab Revenue Market Share by Application (2017-2028)
  • Figure 80. Middle East and Africa Adalimumab Sales Share by Country (2017-2028)
  • Figure 81. Middle East and Africa Adalimumab Revenue Share by Country (2017-2028)
  • Figure 82. Turkey Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 83. Saudi Arabia Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 84. U.A.E Adalimumab Revenue (2017-2028) & (US$ Million)
  • Figure 85. Adalimumab Value Chain
  • Figure 86. Adalimumab Production Process
  • Figure 87. Channels of Distribution
  • Figure 88. Distributors Profiles
  • Figure 89. Bottom-up and Top-down Approaches for This Report
  • Figure 90. Data Triangulation
  • Figure 91. Key Executives Interviewed
目次

This research report focuses on the Adalimumab Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Adalimumab Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Adalimumab Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Adalimumab
    • 1.2.3 Adalimumab Biosimilar
  • 1.3 Market by Application
    • 1.3.1 Global Adalimumab Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Adults
    • 1.3.3 Children
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Adalimumab Sales Estimates and Forecasts 2017-2028
  • 2.2 Global Adalimumab Revenue Estimates and Forecasts 2017-2028
  • 2.3 Global Adalimumab Revenue by Region: 2017 VS 2021 VS 2028
  • 2.4 Global Adalimumab Sales by Region
    • 2.4.1 Global Adalimumab Sales by Region (2017-2022)
    • 2.4.2 Global Sales Adalimumab by Region (2023-2028)
  • 2.5 Global Adalimumab Revenue by Region
    • 2.5.1 Global Adalimumab Revenue by Region (2017-2022)
    • 2.5.2 Global Adalimumab Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Adalimumab Sales by Manufacturers
    • 3.1.1 Global Top Adalimumab Manufacturers by Sales (2017-2022)
    • 3.1.2 Global Adalimumab Sales Market Share by Manufacturers (2017-2022)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Adalimumab in 2021
  • 3.2 Global Adalimumab Revenue by Manufacturers
    • 3.2.1 Global Adalimumab Revenue by Manufacturers (2017-2022)
    • 3.2.2 Global Adalimumab Revenue Market Share by Manufacturers (2017-2022)
    • 3.2.3 Global Top 10 and Top 5 Companies by Adalimumab Revenue in 2021
  • 3.3 Global Adalimumab Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Adalimumab Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Adalimumab Sales by Type
    • 4.1.1 Global Adalimumab Historical Sales by Type (2017-2022)
    • 4.1.2 Global Adalimumab Forecasted Sales by Type (2023-2028)
    • 4.1.3 Global Adalimumab Sales Market Share by Type (2017-2028)
  • 4.2 Global Adalimumab Revenue by Type
    • 4.2.1 Global Adalimumab Historical Revenue by Type (2017-2022)
    • 4.2.2 Global Adalimumab Forecasted Revenue by Type (2023-2028)
    • 4.2.3 Global Adalimumab Revenue Market Share by Type (2017-2028)
  • 4.3 Global Adalimumab Price by Type
    • 4.3.1 Global Adalimumab Price by Type (2017-2022)
    • 4.3.2 Global Adalimumab Price Forecast by Type (2023-2028)

5 Market Size by Application

  • 5.1 Global Adalimumab Sales by Application
    • 5.1.1 Global Adalimumab Historical Sales by Application (2017-2022)
    • 5.1.2 Global Adalimumab Forecasted Sales by Application (2023-2028)
    • 5.1.3 Global Adalimumab Sales Market Share by Application (2017-2028)
  • 5.2 Global Adalimumab Revenue by Application
    • 5.2.1 Global Adalimumab Historical Revenue by Application (2017-2022)
    • 5.2.2 Global Adalimumab Forecasted Revenue by Application (2023-2028)
    • 5.2.3 Global Adalimumab Revenue Market Share by Application (2017-2028)
  • 5.3 Global Adalimumab Price by Application
    • 5.3.1 Global Adalimumab Price by Application (2017-2022)
    • 5.3.2 Global Adalimumab Price Forecast by Application (2023-2028)

6 North America

  • 6.1 North America Adalimumab Market Size by Type
    • 6.1.1 North America Adalimumab Sales by Type (2017-2028)
    • 6.1.2 North America Adalimumab Revenue by Type (2017-2028)
  • 6.2 North America Adalimumab Market Size by Application
    • 6.2.1 North America Adalimumab Sales by Application (2017-2028)
    • 6.2.2 North America Adalimumab Revenue by Application (2017-2028)
  • 6.3 North America Adalimumab Market Size by Country
    • 6.3.1 North America Adalimumab Sales by Country (2017-2028)
    • 6.3.2 North America Adalimumab Revenue by Country (2017-2028)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Adalimumab Market Size by Type
    • 7.1.1 Europe Adalimumab Sales by Type (2017-2028)
    • 7.1.2 Europe Adalimumab Revenue by Type (2017-2028)
  • 7.2 Europe Adalimumab Market Size by Application
    • 7.2.1 Europe Adalimumab Sales by Application (2017-2028)
    • 7.2.2 Europe Adalimumab Revenue by Application (2017-2028)
  • 7.3 Europe Adalimumab Market Size by Country
    • 7.3.1 Europe Adalimumab Sales by Country (2017-2028)
    • 7.3.2 Europe Adalimumab Revenue by Country (2017-2028)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Adalimumab Market Size by Type
    • 8.1.1 Asia Pacific Adalimumab Sales by Type (2017-2028)
    • 8.1.2 Asia Pacific Adalimumab Revenue by Type (2017-2028)
  • 8.2 Asia Pacific Adalimumab Market Size by Application
    • 8.2.1 Asia Pacific Adalimumab Sales by Application (2017-2028)
    • 8.2.2 Asia Pacific Adalimumab Revenue by Application (2017-2028)
  • 8.3 Asia Pacific Adalimumab Market Size by Region
    • 8.3.1 Asia Pacific Adalimumab Sales by Region (2017-2028)
    • 8.3.2 Asia Pacific Adalimumab Revenue by Region (2017-2028)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America Adalimumab Market Size by Type
    • 9.1.1 Latin America Adalimumab Sales by Type (2017-2028)
    • 9.1.2 Latin America Adalimumab Revenue by Type (2017-2028)
  • 9.2 Latin America Adalimumab Market Size by Application
    • 9.2.1 Latin America Adalimumab Sales by Application (2017-2028)
    • 9.2.2 Latin America Adalimumab Revenue by Application (2017-2028)
  • 9.3 Latin America Adalimumab Market Size by Country
    • 9.3.1 Latin America Adalimumab Sales by Country (2017-2028)
    • 9.3.2 Latin America Adalimumab Revenue by Country (2017-2028)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

10 Middle East and Africa

  • 10.1 Middle East and Africa Adalimumab Market Size by Type
    • 10.1.1 Middle East and Africa Adalimumab Sales by Type (2017-2028)
    • 10.1.2 Middle East and Africa Adalimumab Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa Adalimumab Market Size by Application
    • 10.2.1 Middle East and Africa Adalimumab Sales by Application (2017-2028)
    • 10.2.2 Middle East and Africa Adalimumab Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa Adalimumab Market Size by Country
    • 10.3.1 Middle East and Africa Adalimumab Sales by Country (2017-2028)
    • 10.3.2 Middle East and Africa Adalimumab Revenue by Country (2017-2028)
    • 10.3.3 Turkey
    • 10.3.4 Saudi Arabia

11 Company Profiles

  • 11.1 AbbVie
    • 11.1.1 AbbVie Corporation Information
    • 11.1.2 AbbVie Overview
    • 11.1.3 AbbVie Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.1.4 AbbVie Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 AbbVie Recent Developments
  • 11.2 Amgen
    • 11.2.1 Amgen Corporation Information
    • 11.2.2 Amgen Overview
    • 11.2.3 Amgen Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.2.4 Amgen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Amgen Recent Developments
  • 11.3 Sandoz
    • 11.3.1 Sandoz Corporation Information
    • 11.3.2 Sandoz Overview
    • 11.3.3 Sandoz Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.3.4 Sandoz Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Sandoz Recent Developments
  • 11.4 Boehringer Ingelheim
    • 11.4.1 Boehringer Ingelheim Corporation Information
    • 11.4.2 Boehringer Ingelheim Overview
    • 11.4.3 Boehringer Ingelheim Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.4.4 Boehringer Ingelheim Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Boehringer Ingelheim Recent Developments
  • 11.5 Mylan
    • 11.5.1 Mylan Corporation Information
    • 11.5.2 Mylan Overview
    • 11.5.3 Mylan Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.5.4 Mylan Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Mylan Recent Developments
  • 11.6 Biogen
    • 11.6.1 Biogen Corporation Information
    • 11.6.2 Biogen Overview
    • 11.6.3 Biogen Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.6.4 Biogen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Biogen Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Adalimumab Industry Chain Analysis
  • 12.2 Adalimumab Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Adalimumab Production Mode & Process
  • 12.4 Adalimumab Sales and Marketing
    • 12.4.1 Adalimumab Sales Channels
    • 12.4.2 Adalimumab Distributors
  • 12.5 Adalimumab Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Adalimumab Industry Trends
  • 13.2 Adalimumab Market Drivers
  • 13.3 Adalimumab Market Challenges
  • 13.4 Adalimumab Market Restraints

14 Key Findings in The Global Adalimumab Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer